KT 621
Alternative Names: KT-621Latest Information Update: 28 Oct 2024
At a glance
- Originator Kymera Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Immunological disorders